

SEDOGEST

Ursodeoxycholic Acid 150 mg, 300 mg and Sustained Release 450 mg Tablets


SEDOGEST

Ursodeoxycholic Acid 150 mg, 300 mg and Sustained Release 450 mg Tablets

Description:

SEDOGEST 150/300/450-SR contains Ursodeoxycholic Acid that belongs to the group of medicines called Hepatoprotective
agents. It is used to dissolve gallstones in various liver-related disorders such as cirrhosis, sclerosing cholangitis, and liver
dysfunction.

Indication:



Mechanism of action:

- Ursodeoxycholic acid reduces elevated liver enzyme levels by facilitating bile flow through the liver and protecting liver cells. The main mechanism is anticholelithic.
- It is concentrated in bile and decreases biliary cholesterol by:
 - 1. Suppressing hepatic synthesis and secretion of cholesterol
 - 2. Inhibiting its intestinal absorption
- The reduced cholesterol saturation permits the gradual solubilization of cholesterol from gallstones, resulting in their eventual dissolution.

Key Features:

- UDCA delays the progression rate of PBC resulting in decreased need for liver transplantation.¹
- Treatment of PSC patients with high dose UDCA (25-30 mg/kg per day) for 1 year led to improved biochemistries and the Mayo risk score. 1
- UDCA improve maternal itching scores and liver function tests without interfering with the fetoplacental estrogen production in patient with ICP(Intrahepatic Cholestasis of Pregnancy).²
- UDCA is well tolerated by pregnant women. No fetal or neonatal side-effects are detected.²
- UDCA has been used in the treatment of gallbladder stone as an alternative to cholecystectomy.
- UDCA is an effective and safe alternative to Vitamin E in non diabetic-non cirrhotic Indian NAFLD patients.

Dosage:

As directed by Physician.

Presentation:

• SEDOGEST 150/300/450-SR is available as a strip of 10 Tablets.

Storage:

Store in cool and dry place. Protected from light and moisture.

References:

1. Journal of Hepatology; 35:2001:134-146 | 2. Arch Gynecol Obstet; 289(3):2014:541-7 | 3. Saudi J Gastroenterol; 22(3):2016:192-197

La Renon Healthcare Private Limited

